Cerebrovascular Attack Research Articles

Role of Preoperative Inflammatory Blood Cell Indexes as a Postoperative Risk Predictor Among Patients Undergoing On-Pump Cardiac Surgery.

Estimating patient risk before heart surgery (HS) is crucial. Perioperative inflammation is associated with several complications and mortality. This study investigated blood cell count inflammatory indices (BCCII) to predict risks, including neutrophil-to-lymphocyte ratio (NLR), derivate NLR (DNLR), neutrophil-to-platelet-lymphocyte ratio (NLPR), lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio (PLR), Systemic Inflammatory Index (SII), Systemic Inflammatory Reaction Index (SIRI), and Aggregate Index of Systemic Inflammation (AISI). Data from a cohort of patients undergoing on-pump HS at a single center in Brazil were retrospectively analyzed. Data were obtained from medical records and a laboratory analyzer, and SPSS version 20.0 was used for index calculations and statistical analyses. In total, 444 surgeries were performed, and 40 in-hospital deaths occurred. Except for PLR, all other indexes were independent predictors of death after multivariate adjustment (all p < 0.05). Discrimination performance was absent for PLR and AISI, and NLR, NLPR, and DNLR demonstrated the best area under the receiver operating characteristic curve (AUC > 0.7; all p < 0.0001). For survivors (n = 404), all indexes exhibited a correlation with the length of hospital stay (all p < 0.03), and NLR, NLPR, and DNLR were predictors (p < 0.026) of poor operative outcomes (acute myocardial infarction, cerebrovascular attack, cardiac arrest, low cardiac output, prolonged mechanical ventilation, renal failure, and sepsis). All BCCII scores were associated with length of hospital stay. Apart from PLR, all indexes were independent predictors of in-hospital mortality. Accuracy was highest for NLR, NLPR, and DNLR; for survivors, these three factors were good predictors of poor operative outcomes.

Complications associated with kidney transplantation, causes of graft failure and mortality following kidney transplantation in patients with systemic lupus erythematosus: a meta-analysis

IntroductionDespite improvement in the management of systemic lupus erythematosus (SLE) during the past two decades, 10–22% of patients with lupus nephritis (LN) will progress to end-stage renal disease (ESRD). Kidney transplantation is among the possible treatment for patients with SLE progressing to ESRD. However, the issue with kidney transplantation in patients with SLE is controversial. In this analysis, we aimed to compare the complications associated with kidney transplantation, causes of graft failure and causes of mortality following kidney transplantation in patients with SLE with ESRD.MethodsThe sources of data included http://www.ClinicalTrials.gov, EMBASE, MEDLINE, Google Scholar, Web of Science and the Cochrane database. Revman software version 5.4 was used for the data analysis whereby risk ratio (RR) with 95% confidence intervals (CI) were used to represent data following analysis. In addition, the Q statistic test and the I2 statistic test were used to assess heterogeneity. A random effect statistical model was used and a subgroup outcome with a P-value less than 0.05 was considered statistically significant.ResultsA total number of 149,330 participants enrolled between the years 1968 and 2018 were included in this analysis with 7534 participants with SLE.Results of this analysis showed that mortality (RR 1.07, 95% CI 0.89–1.29; P = 0.45), graft failure (RR 1.22, 95% CI 0.99–1.55; P = 0.07) and delayed graft function (RR 1.01, 95% CI 0.44–2.34; P = 0.98) were not significantly higher in renal transplant patients with SLE versus a control group. When the causes of graft failure were analysed in renal transplant patients with SLE versus without SLE, acute graft rejection (RR 1.20, 95% CI 0.98–1.47; P = 0.07), chronic graft rejection (RR 0.76, 95% CI 0.57–1.03; P = 0.08), graft thrombosis (RR 1.47, 95% CI 0.83–2.63; P = 0.19), recurrence of disease (RR 3.08, 95% CI 1.00–9.47; P = 0.05) and chronic allograft nephropathy (RR 1.08, 95% CI 0.60–1.95; P = 0.80) were also not significantly higher in patients with SLE. On the basis of the analysis, mortality from any cardiac cause (RR 0.82, 95% CI 0.67–1.01; P = 0.06), sepsis (RR 1.19, 95% CI 0.93–1.53; P = 0.17), malignancy (RR 0.79, 95% CI 0.51–1.24; P = 0.31) and cerebrovascular attack (RR 0.76, 95% CI 0.44–1.30; P = 0.31) were not significantly different in kidney transplantation patients with versus without SLE.ConclusionsComplications associated with kidney transplantation including mortality, graft failure and delayed graft function were not significantly higher in patients with SLE when compared with a control group. The causes of graft failure and mortality after kidney transplantation were also comparable in both groups. Therefore, kidney transplantation represents a promising treatment in patients with SLE with ESRD.

Reversible encephalitis-like episodes in fragile X-associated tremor/ataxia syndrome: a case report

BackgroundFragile X-associated tremor/ataxia syndrome (FXTAS) is a neurodegenerative disorder caused by CGG repeat expansion of FMR1 gene. Both FXTAS and neuronal intranuclear inclusion disease (NIID) belong to polyglycine diseases and present similar clinical, radiological, and pathological features, making it difficult to distinguish these diseases. Reversible encephalitis-like attacks are often observed in NIID. It is unclear whether they are presented in FXTAS and can be used for differential diagnosis of NIID and FXTAS.Case presentationA 63-year-old Chinese male with late-onset gait disturbance, cognitive decline, and reversible attacks of fever, consciousness impairment, dizziness, vomiting, and urinary incontinence underwent neurological assessment and examinations, including laboratory tests, electroencephalogram test, imaging, skin biopsy, and genetic test. Brain MRI showed T2 hyperintensities in middle cerebellar peduncle and cerebrum, in addition to cerebellar atrophy and DWI hyperintensities along the corticomedullary junction. Lesions in the brainstem were observed. Skin biopsy showed p62-positive intranuclear inclusions. The possibilities of hypoglycemia, lactic acidosis, epileptic seizures, and cerebrovascular attacks were excluded. Genetic analysis revealed CGG repeat expansion in FMR1 gene, and the number of repeats was 111. The patient was finally diagnosed as FXTAS. He received supportive treatment as well as symptomatic treatment during hospitalization. His encephalitic symptoms were completely relieved within one week.ConclusionsThis is a detailed report of a case of FXTAS with reversible encephalitis-like episodes. This report provides new information for the possible and rare features of FXTAS, highlighting that encephalitis-like episodes are common in polyglycine diseases and unable to be used for differential diagnosis.

Novel Oral Anticoagulants in Cardiovascular Practice

In the recent era of medicine, Novel Oral Anticoagulants (Apixaban, Dabigatran, Edoxaban, and Rivaroxaban) have become the preferred drugs for long-term anticoagulation therapy in the majority of cardiovascular conditions, along with non-cardiac co-morbid conditions with few necessary exceptions. This preference is based on their easy availability, therapeutic efficacy, all-cost effectiveness, safety profile, and more convenient usage for both patients and clinicians. Novel Oral Anticoagulants (NOACs) have different pharmacokinetics and pharmacodynamics than oral vitamin K antagonists. This article highlights the basic pharmacology, common complications, available antidotes, and the utility of NOACs in different common cardiovascular diseases requiring long-term oral anticoagulation, including stroke prevention in valvular and non-valvular atrial fibrillation, coronary artery disease, myocardial infarction, left ventricular thrombus and cerebrovascular attacks. NOACs are still underutilized in cardiovascular practice because the concomitant co-morbid conditions hinder a clinician from prescribing these drugs confidently. This manuscript will provide a brief critical overview to help clinicians prescribe NOACs more conveniently.

OUTCOMES OF ROTATIONAL ATHERECTOMY IN CALCIFIED PROXIMAL LEFT ANTERIOR DESCENDING (LAD) LESIONS IN THE CONTEXT OF TRIPLE VESSEL DISEASE

Percutaneous coronary intervention (PCI) has become more complex with the advancement of medical devices. One such device is the rotational atherectomy (RA), which uses a rotating diamond-coated burr to modify calcified lesions. This makes it easier to deliver balloons and stents to specific lesions. However, there is a lack of literature regarding the success of RA in calcified proximal 'left anterior descending (LAD) lesions' following PCI. To address this gap, a study was conducted to evaluate the clinical outcomes of RA in calcified proximal LAD lesions in triple vessel disease (TVD). The study included 112 patients who underwent PCI using RA between February 2022 and November 2022 at Lady Reading Hospital, Peshawar. Data was collected using a standard report structure, including operative and follow-up details and medical and demographic features. Retrospective data was collected using medical records and interviews with patients or doctors. The ethical committee approved the study. The participants had an average age of 68.4± 0.45 years, with 85 men (75.8%) and 40 (35.7%) with diabetes mellitus. The technical success rate was 97.6%, with 20 individuals (17.8%) experiencing significant adverse cerebral and cardiac events while hospitalized. At 1.5 years, 25 (22.3%) TVFs had occurred. Independent variables such as current smoking, chronic renal disease, history of cerebrovascular attack, left ventricle ejection fraction, and left central disease were assessed to predict TVF. Based on the results, the investigation showed that rotational atherectomy in calcified proximal LAD lesions had promising success rates.

The effect of B-vitamins on the prevention and treatment of cardiovascular diseases: a systematic review and meta-analysis.

Previous research evaluating the effects in B-vitamins on the prevention and treatment of cardiovascular disease (CVD) has substantial limitations and lacks recently published large prospective studies; hence, conducting an updated meta-analysis is needed. We investigated the association between vitamin B status and human CVD development in order to provide more specific advice about vitamin B intake for those at risk of CVD. Relevant articles were identified by JSTOR, PubMed, and ProQuest databases. Key words used to identify the studies included the different combinations of B-vitamins, folate, folic acid, vitamin B6, vitamin B12, homocysteine, cardiovascular disease, stroke, coronary disease, myocardial infarction, and cerebrovascular and transient ischemic attack. The database search was supplemented by hand-searching of reference lists of selected articles. Pooled estimates were calculated from the mean differences using a random-effects model. Supplementation with folic acid was reported to have a clinical benefit of significantly reducing carotid intima-media thickness. Higher intakes of folic acid, vitamin B6, and vitamin B12 were generally associated with a lower risk of CVD in the general population, except in those without normal renal function and those with unstable angina or past non-ST-elevation myocardial infarction. Vitamin B supplementation resulted in the greatest cardiovascular benefit in those with normal renal function and without unstable angina or non-ST-elevation myocardial infarction recently. Factors such as age, gender, and genetic polymorphisms contribute to varying effects.

Current Biomarkers for Carotid Artery Stenosis: A Comprehensive Review of the Literature.

Carotid artery stenosis (CAS), an atherosclerotic disease of the carotid artery, is one of the leading causes of transient ischemic attacks (TIA) and cerebrovascular attacks (CVA). The atherogenic process of CAS affects a wide range of physiological processes, such as inflammation, endothelial cell function, smooth muscle cell migration and many more. The current gold-standard test for CAS is Doppler ultrasound; however, there is yet to be determined a strong, clinically validated biomarker in the blood that can diagnose patients with CAS and/or predict adverse outcomes in such patients. In this comprehensive literature review, we evaluated all of the current research on plasma and serum proteins that are current contenders for biomarkers for CAS. In this literature review, 36 proteins found as potential biomarkers for CAS were categorized in to the following nine categories based on protein function: (1) Inflammation and Immunity, (2) Lipid Metabolism, (3) Haemostasis, (4) Cardiovascular Markers, (5) Markers of Kidney Function, (6) Bone Health, (7) Cellular Structure, (8) Growth Factors, and (9) Hormones. This literature review is the most up-to-date and current comprehensive review of research on biomarkers of CAS, and the only review that demonstrated the several pathways that contribute to the initiation and progression of the disease. With this review, future studies can determine if any new markers, or a panel of the proteins explored in this study, may be contenders as diagnostic or prognostic markers for CAS.

Prevalence of Pressure Injury among Stroke Patients In and Out of Healthcare Settings: A Systematic Review and Meta-Analysis.

Pressure injury is a recognized problem for patients with stroke. Knowing the prevalence of pressure injury post stroke can guide clinical professionals and researchers to take appropriate actions for patient care and education. The aim of this study was to systematically review the literature regarding prevalence of pressure injury among patients with stroke in the hospital, and in the home with no home healthcare services and nursing homes. Original articles available in Scopus, Web of Science, PubMed, ProQuest, and Google Scholar databases were searched separately by two researchers using the following keywords: stroke, cerebrovascular attack, pressure injury, pressure ulcer, bedsore, decubitus ulcer, and prevalence. The search was performed according to the PRISMA flow diagram from 2000 to 2020. After the initial review, 14 articles conducted between 2008 and 2019 were included in the final analysis. Eight studies were conducted in healthcare settings, and six studies were conducted out of hospitals. The estimated pooled prevalence for pressure injury in all studies was 3.9%. The estimated pooled prevalence for pressure injury in studies conducted in hospitals and in patients' homes with no home healthcare services and nursing homes were 3.06 and 17.25, respectively. The prevalence of pressure injury among stroke patients after hospital discharge was significantly higher than when they were hospitalized. This could indicate that this group of patients do not receive adequate care and attention for pressure injury after hospital discharge. Given the limitations of the available studies, it is recommended that further studies be conducted on pressure injury among stroke patients both at the time of hospitalization and after hospital discharge.

Clinical and laboratory predictors for disease progression in patients with COVID-19: A multi-center cohort study

BackgroundReliable clinical and laboratory predictors of coronavirus disease 2019 (COVID-19) disease progression could help to identify the subset of patients who are susceptible to severe symptoms. This study sought to identify the predictors for disease progression in patients with COVID-19. MethodsThis study recruited consecutive patients from four hospitals between March 1, 2020, and July 31, 2021. Demographic characteristics, laboratory results, and clinical outcomes were collected. ResultsAmong the 239 enrolled patients, 39.3% (94/239) experienced in-hospital disease progression. Multivariate logistic regression revealed that coronary arterial disease (CAD) (OR, 4.15; 95% C.I., 1.47–11.66), cerebrovascular attack (CVA) (OR, 12.98; 95% C.I., 1.30–129.51), platelet count < median value (OR, 3.23; 95% C.I., 1.65–6.32), and C-reactive protein (CRP) levels > median value of (OR, 2.25; 95% C.I., 1.02–4.99) were independent factors associated with COVID-19 progression. Patients who underwent disease progression at days 1, 4, and 7 presented lower lymphocyte counts and higher CRP levels, compared to patients without disease progression. ConclusionsThe study revealed that in hospitalized COVID-19 patients, comorbidity with CAD and CVA, low platelet count, and elevated CRP levels were independently associated with disease progression. Compared with patients without disease progression, those with disease progression presented persistently low lymphocyte counts and elevated CRP levels.

Comparison of Nasalance Scores with and without Hypernasality Control Device in Adults with Hypernasality: A Preliminary Study

The purpose of this study was to compare nasalance scores of the experimental vowels, words and paragraphs with and without ‘Hypernasality Control Device (HCD)’ in adults with hypernasality. Three adults with a cerebrovascular attack or a Parkinson’s disease wore in HCD, were asked to read aloud the experimental vowels, words and paragraphs. Using a Nasometer, the nasalance scores were measured. In all experimental vowels, words and paragraphs, the nasalance scores with HCD were measured lower than those without HCD. These results showed that HCD played a role in regulating nasal resonance in adults with hypernasality. However, various modifications and trials of HCD are required for the adequate modulation of nasal resonance. Additional studies are also required for adults with various degrees of hypernasality.

NT-proBNP Levels Influence the Prognostic Value of Mineral Metabolism Biomarkers in Coronary Artery Disease.

Background. Mineral metabolism (MM) system and N-terminal pro-brain natriuretic peptide (NT-ProBNP) have been shown to add prognostic value in patients with stable coronary artery disease (SCAD). However, the influence of NT-ProBNP on the prognostic role of MM in patients with SCAD has not been shown yet. The objective of this study is to assess the influence of NT-ProBNP on the prognostic role of MM markers in patients with SCAD. Methods: We analyzed the prognostic value of MM markers (parathormone (PTH), klotho, phosphate, calcidiol (25-hydroxyvitamin D3), and fibroblast growth factor-23) in 964 patients with SCAD and NT-ProBNP > 125 pg/mL vs. patient with NT-ProBNP ≤ 125 pg/mL included in five hospitals in Spain. The main outcome was the combination of death, heart failure, and ischemic events (any acute coronary syndrome, ischemic stroke, or transient ischemic attack). Results: A total of 622 patients had NT-proBNP > 125 pg/mL and 342 patients had NT-ProBNP ≤ 125 pg/mL. The median follow-up was 5.1 years. In the group of NT-proBNP > 125 pg/mL, the patients were older, and there were more females and smokers than in the group of patients with normal NT-proBNP. Additionally, the proportion of patients with hypertension, atrial fibrillation, ejection fraction < 40%, cerebrovascular attack, or prior coronary artery bypass graft was higher in the high NT-proBNP group. In the high NT-proBNP patients, the predictors of poor prognosis were PTH (HR = 1.06 (1.01–1.10), p < 0.001) and NT-proBNP (HR = 1.02 (1.01–1.03), p = 0.011), along with age (HR = 1.039 (1.02–1.06), p < 0.001), prior coronary artery bypass graft (HR = 1.624 (1.02–2.59), p = 0.041), treatment with statins (HR = 0.32 (0.19–0.53), p < 0.001), insulin (HR = 2.49 (1.59–4.09), p < 0.001), angiotensin receptor blockers (HR = 1.73 (1.16–2.56), p = 0.007), nitrates (HR = 1.65 (1.10–2.45), p = 0.014), and proton pump inhibitors (HR = 2.75 (1.74–4.36), p < 0.001). In the NT-proBNP ≤ 125 pg/mL subgroup, poor prognosis predictors were plasma levels of non-high-density lipoprotein (non-HDL) cholesterol (HR = 1.01 (1.00–1.02), p = 0.014) and calcidiol (HR = 0.96 (0.92–0.99), p = 0.045), as well as treatment with verapamil (HR = 11.28 (2.54–50.00), p = 0.001), and dihydropyridines (HR = 3.16 (1.63–6.13), p = 0.001). Conclusion: In patients with SCAD and NT-ProBNP > 125 pg/mL, PTH and NT-ProBNP, which are markers related to ventricular damage, are predictors of poor outcome. In the subgroup of patients with NT-ProBNP ≤ 125 pgm/L, calcidiol and non-HDL cholesterol, which are more related to vascular damage, are the independent predictors of poor outcome. Then, in patients with SCAD, baseline NT-ProBNP may influence the type of biomarker that is effective in risk prediction.

Outcomes of Geriatric Patients with Hepatocellular Carcinoma.

Background: The treatment modalities and outcomes of geriatric patients with hepatocellular carcinoma (HCC) remain controversial. This retrospective observational cohort study compared the outcomes of HCC between geriatric and younger patients. Methods: The medical records of patients with HCC managed between January 2001 and December 2017 were retrieved from the Chang Gung Memorial Hospital Research Database. Patients were stratified by age into two groups: a geriatric group (65–75 years) and a younger group (<65 years). The two groups were matched through 1:2 propensity score matching (PSM) according to sex, cardiovascular disease, cerebrovascular attack, diabetes mellitus, cirrhosis, hepatitis, and hypertension. Results: Of the 11,033 patients with HCC, 2147 patients aged 65–75 years and 4294 patients aged <65 years were identified after 1:2 PSM. The Kaplan–Meier model revealed that the HCC outcomes in patients older than 65 years were not significantly different after 3 years (p = 0.060). Consistent results were also obtained when the laboratory data associated with HCC incidence were included in the Fine–Gray competing risk model after 1:2 PSM (p = 0.1695). The major risk factors for HCC survival were systemic immune-inflammation index (SII) ≥ 610 × 109 cells/L, advanced tumor stage, and model for end-stage liver disease (MELD) score, etc. Conclusion: Age was not an independent factor for mortality in patients with HCC in the first 3 years. Geriatric patients with HCC should be as aggressively managed as younger patients.

Recent Synergy of Nanodiamonds: Role in Brain-Targeted Drug Delivery for the Management of Neurological Disorders.

The aim of the present review article is to summarize the role of nanodiamonds in various neurological diseases. We have taken related literature of making this review article from ScienceDirect, springer, Research gate, PubMed, Sci-finder, etc. The current approaches for treating neurological conditions such as glioblastoma includes chemotherapy or combination anti-retro viral therapy for HIV (human immunodeficiency virus) or use of anti-Alzheimer drugs during cognitive impairment. These approaches can provide only symptomatic relief as they do not target the cause of the disease due to their inability to penetrate the blood brain barrier. On long-term use, they may cause CNS toxicity due to accumulation in the brain. So nanodiamonds could prove as a promising approach in the brain targeting of the bioactive and to treat many neurological disorders such as Alzheimer's disease, Parkinson's disease, brain tumor (glioblastoma), HIV, amyotrophic multiple sclerosis, Huntington disease, stroke (cerebrovascular attack), batten disease, schizophrenia, epilepsy, and bacterial infections (encephalitis, sepsis, and meningitis) due to their ability to penetrate the blood-brain barrier and owing to their excellent surface properties, i.e., nano size and high surface area, ease of functionalization, multiple drug binding, and biocompatibility; they can be useful for brain targeted drug delivery with minimal side effects.

Cerebral Venous Thrombosis without Thrombocytopenia after COVID-19 Vaccination

Cerebral venous thrombosis (CVT) is a rare form of cerebrovascular attack and its predisposing factors commonly co-exist. In the coronavirus disease 2019 (COVID-19) era, various side effects of COVID-19 vaccine have been reported, and CVT is one of the well-known types. It is usually explained as prothrombotic immune thrombocytopenia by an antibody binding to platelet factor 4 receptor. However, some cases are irrelevant to thrombocytopenia and calls for a new explanation. Here we report a case of CVT without thrombocytopenia after COVID-19 vaccination.

ISCHEMIC CEREBROVASCULAR ACCIDENT IN A NONAGENARY PATIENT

Acute cerebrovascular attack (CVA) is the second cause of death in the world and generates high costs in its treatment and recovery, as well as a great socioeconomic impact, since it is the main cause of longterm disability. Although simple brain computed tomography (CT) is still the image recommended by international guidelines for the initial evaluation and decision-making on the management of patients with suspected stroke, in recent years there have been extraordinary advances in timely diagnosis and early stroke with new tools that range from the standardization of cerebral computed tomography angiography as one of the main studies in the initial approach to the use of brain tomography and magnetic resonance imaging (MRI) perfusion techniques, which make it possible to establish the nucleus of the infarct and the potentially salvageable surrounding area, so it is possible to offer therapies that provide the patient with functionality and quality of life in the medium and long term. Taking into account the above, we are encouraged to present this case, of an elderly patient who presented this pathology, where the intestinal ileum was also added. Objective: To describe cerebral infarction in a nonagenarian affected patient. Design: Prospective, observational in a single center. Methodology: This is a systematic review of cerebral infarction in a nonagenarian patient, emphasizing its clinical characteristics and short-term complications. The information and images obtained belong to the medical personnel in charge of the case, whose reinforcements rest on the statistical package Excel, Word and JPG.

Clinical particularities regarding rehabilitation treatment of a young patient with right pontine ischemic stroke, resulting in dysarthria and left side brachial and crural hemiparesis, and quite recent COVID-19 history

Introduction. Cerebrovascular attacks are one of the leading causes of mortality and morbidity in the world. The most severe are considered to be pontine strokes, because of the high risk of vital functions impairment. The clinical presentation of a pontine stroke can vary from the clas-sical crossed syndrome (ipsilateral cranial nerve palsy and contralateral motor and/or sensory impairment) to pure motor hemiplegia or pure sensory stroke, which are less common.1 Materials and methods. This presentation describes the case of a 39-year-old patient with a re-cent history of untreated SARS-COV 2 infection that was followed in the next month by a sudden onset of facial paralysis, dysarthria and a progressive left hemiplegia. The patient’s functional status was assessed in our Neuromuscular Clinical Division and he underwent a rehabilitation program consisting of physical, occupational and speech therapies. Multidisciplinary efforts were made in order to find the underlying cause of the pontine ischemic stroke. Results. The patient had a personal history of cardiovascular disease risk factors (essential hy-pertension and hyperlipidaemia), without other pathological brain imagining outcomes and normal bleeding tests. The suspicion of an interatrial communication was raised. The patient managed to rapidly maintain the standing posture and to practice walking with unilateral sup-port. At discharge, the facial paralysis and dysarthria were almost completely remitted. The left brachial extremity also showed signs of improvement, as the patient was able to perform flexion and extension movements of the fingers, wrist and forearm. Conclusion. To conclude, the patient’s evolution was favourable, although the certain cause of the underlying stroke has not been clarified. The neurological complications of COVID-19 in-clude ischemic strokes, and cases were reported in young adults too2,3. If this were the case, pre-vention of further cerebrovascular attacks and their complications is necessary1. Caution in terms of medium/long-term prophylactic anticoagulant therapy and careful control of associated cardiovascular disease risk factors has been proposed and discussed in the multidisciplinary team: rehabilitation physician, neurologist, cardiologist. Keywords: cerebrovascular attacks, COVID-19, cardiovascular disease risk factors, ischemic strokes, reha-bilitation

Abstract 11897: Prevalence of Abnormalities of Mineral Metabolism in Patients With Stable Coronary Artery Disease According to Renal Function

Background: Disturbances of mineral metabolism (MM) are present in pts. with stable coronary artery disease (SCAD) and average renal function. However, differences in these abnormalities in pts. with or without renal disease have not been reported previously. Purpose To describe the differences in MM markers (phosphate, calcidiol, parathormone [PTH], fibroblast growth factor23 [FGF23] and klotho) in patients with SCAD and estimated glomerular filtration rate (eGFR)&lt;60 ml/min/1.73 m2 (LGFR) vs pts. with eGFR≥60 ml/min/1.73 m2 (HGFR). Methods: We analyzed MM parameters in 964 patients with SCAD in five hospitals of Spain. Patients were divided in two subgroups: LGFR and HGFR. Total death was assessed during follow-up. eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation. Results: There were 790 pts. with HGFR and 174 with LGFR. Pts with LGFR were older and had more incidence of hypertension, diabetes, peripheral artery disease, history of cerebrovascular attack and prior coronary artery by-pass graft than those with HGFR. Left ventricular ejection fraction&lt;40%, and previous diagnoses of heart failure, and atrial fibrillation were also more common in LGFR pts. Phosphate, FGF23 and PTH plasma levels were higher in LFGR pts., while klotho levels were lower in this subgroup. Calcidiol plasma levels did not show significant differences between both subgroups. During follow-up (median 5.1 years), death by any cause was more frequent in patients with LGFR vs HGFR (17.2% vs 5.7%, respectively; p&lt;0.001). Conclusion: Pts. with SCAD and eGFR&lt;60 ml/min/1.73 m2 show lower klotho plasma levels, higher levels of phosphate, FGF23, and PTH, and increased mortality than those with eGFR≥60 ml/min/1.73 m2.

A study to compare task-based mirror therapy versus constraint induced movement therapy for hand function in hemiplegic subjects

Introduction and Aim:To find the effectiveness of task-based mirror therapy when compared with constraint-induced movement therapy for hand function in hemiplegic subjects. Stroke is a major health problem in the world. According to various researches, 70%-80% of the patients have the upper extremity impairment then lower extremity. Task-based mirror therapy can be an effective management for premotor cortex impairment. Constraint-induced movement therapy forms the new neural pathway when used properly.&#x0D; &#x0D; Materials and Methods:30 patients with subacute CVA (cerebrovascular attack) were enrolled and randomly divided into two groups: constraint-induced movement therapy (CIMT) and task-based mirror therapy (TMBT). The full-Meyer motor function assessment was evaluated 4 weeks after treatment.&#x0D; &#x0D; Results: The results showed that mean value of TMBT (pre-test – 5.733, post-test- 9.86) and SD of (pre-test- 1.67, post-test- 1.92) and in CIMT(pre-test-6.3, post-test-11.13) and SD (Pre-test-1.45,Post-test -1.36).&#x0D; &#x0D; Conclusion:This study shows that CIMT group showed more improvement than TMBT group.

The efficacy of three dimensional echocardiography in assessment of aortic atherosclerotic plaques compared to two dimensional echocardiography

Abstract Background Complex aortic atherosclerotic plaques (AAPs) carry a significant risk of embolism. Currently, two-dimensional (2D) transesophageal echocardiography (TEE) is the principal diagnostic tool of AAPs. However, we hypothesized that the data obtained from three-dimensional (3D) imaging may improve AAPs' spatial assessment. Purpose This study was aimed to evaluate the efficacy of 3DTEE in assessment of AAPs. Methods This study includes 96 patients who underwent routine TEE in our center within 2018–2019. The entire aorta including aortic root, ascending aorta, aortic arch, and descending thoracic aorta was investigated using both 2D and 3D TEE. The size and grade of aortic atherosclerotic plaques were compared using both 2D and 3D TEE. In addition, we examined to see if there is any correlation between the grade and size of the plaque, and patient's cardiac risk factors including their history of atherosclerotic diseases. Results Patients with atherosclerotic plaque in the ascending aorta had a larger plaque thickness in both two-dimensional and three-dimensional echocardiography. Obesity was an important risk factor for development of AAPs. Also, patients with a history of cerebrovascular attack (CVA) or transient ischemic attach (TIA) had larger AAPs. While age and gender showed no impact on the thickness of AAPs. According to the results obtained from comparing three-dimensional over two-dimensional echocardiography, one patient (1.04%) showed a decrease in grading scale, while nine patients (9.38%) showed enhancement in their grading (P-value=0.03). For the rest of 86 patients (89.58), atherosclerotic plaque grading was similar using both methods. This means that in almost 9% of cases 3D TEE increases the grading of the attributed atherosclerotic plaque, while it is the same to 2DTEE in most cases. Conclusions The information obtained from three-dimensional echocardiography would be most often very similar to the two-dimensional echocardiography, while in few cases, it would improve the grading scale. Cases with obesity and history of CVA and TIA had larger thickness of AAPs in both 2D and 3DTEE, while age and gender had no impact on plaque thickness. Funding Acknowledgement Type of funding sources: None.

Clinical Outcome of Rotational Atherectomy in Calcified Lesions in Korea-ROCK Registry.

Background and Objectives: Data is still limited regarding clinical outcomes of rotational atherectomy (RA) after percutaneous coronary intervention. We sought to evaluate clinical outcomes of RA. Materials and Methods: This multi-center registry enrolled patients who underwent RA during PCI from nine tertiary centers in Korea between January 2010 and October 2019. The primary endpoint was target-vessel failure (TVF; the composite outcome of cardiac death, target-vessel spontaneous myocardial infarction, or target-vessel revascularization). Results: Of 540 patients (583 lesions), the mean patient age was 71.4 ± 0.4 years, 323 patients (59.8%) were men, and 305 patients (56.5%) had diabetes mellitus. Technical success rate was 96.4%. In-hospital major adverse cerebral and cardiac events occurred in 63 cases (10.8%). At 1.5 years, 72 (16.0%) of TVFs were occurred. We evaluated independent predictors of TVF, which included current smoker (hazard ratio (HR), 1.92; 95% confidence interval (CI), 1.17–3.16; p = 0.01), chronic renal disease (HR, 1.87; 95% CI, 1.14–3.08; p = 0.013), history of cerebrovascular attack (HR, 2.14; 95% CI, 1.24-3.68; p = 0.006), left ventricle ejection fraction (HR, 0.98; 95% CI, 0.97–0.999; p = 0.037), and left main disease (HR, 1.94; 95% CI, 1.11–3.37; p = 0.019). Conclusions: From this registry, we demonstrated acceptable success rates, in-hospital and mid-term clinical outcomes of RA in the DES era.